Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GH Research PLC stock logo
GHRS
GH Research
$17.29
+8.1%
$12.58
$6.00
$20.50
$899.60M0.96199,339 shs153,933 shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$12.63
+1.9%
$9.24
$6.44
$17.00
$973.61M0.61929,197 shs4.10 million shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$9.25
+0.4%
$9.95
$8.58
$25.07
$795.96M0.71.86 million shs1.28 million shs
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$22.74
-12.9%
$0.00
$8.13
$34.31
$212.87M0.234,861 shs57,131 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GH Research PLC stock logo
GHRS
GH Research
-3.03%+10.50%+25.31%+83.79%+37.14%
Replimune Group, Inc. stock logo
REPL
Replimune Group
+9.93%+32.76%+26.79%+62.52%+14.71%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-6.50%+5.26%-10.15%-16.65%-62.22%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-12.47%+19.50%+6.05%+2,610,999,900.00%+2,610,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GH Research PLC stock logo
GHRS
GH Research
1.4987 of 5 stars
3.51.00.00.02.40.80.0
Replimune Group, Inc. stock logo
REPL
Replimune Group
4.1119 of 5 stars
3.61.00.04.52.62.50.6
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
3.0683 of 5 stars
3.50.00.04.42.50.00.0
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GH Research PLC stock logo
GHRS
GH Research
3.00
Buy$32.0085.08% Upside
Replimune Group, Inc. stock logo
REPL
Replimune Group
3.13
Buy$21.0066.27% Upside
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
2.90
Moderate Buy$34.10268.65% Upside
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
3.00
Buy$64.25182.54% Upside

Current Analyst Ratings Breakdown

Latest TVRD, GHRS, REPL, and SNDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$16.00 ➝ $19.00
7/15/2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$37.00 ➝ $35.00
7/14/2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$62.00
7/11/2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$52.00
7/10/2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$18.00
7/3/2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
6/24/2025
GH Research PLC stock logo
GHRS
GH Research
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$39.00
6/20/2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
6/12/2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$78.00
6/4/2025
GH Research PLC stock logo
GHRS
GH Research
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$25.00
6/2/2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GH Research PLC stock logo
GHRS
GH Research
N/AN/AN/AN/A$3.44 per shareN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/A$5.40 per shareN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$23.68M33.61N/AN/A$3.38 per share2.74
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/AN/AN/AN/A($3.02) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GH Research PLC stock logo
GHRS
GH Research
-$38.96M-$0.79N/AN/AN/AN/A-19.20%-18.40%9/2/2025 (Estimated)
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$247.30M-$3.07N/AN/AN/AN/A-57.98%-45.21%8/14/2025 (Estimated)
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$318.76M-$3.86N/AN/AN/A-757.53%-101.60%-58.41%8/7/2025 (Estimated)
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-$70.87MN/A0.00N/A-595.39%-710.04%-79.00%N/A

Latest TVRD, GHRS, REPL, and SNDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$0.99N/AN/AN/AN/AN/A
5/22/2025Q4 2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$0.75-$0.82-$0.07-$0.82N/AN/A
5/8/2025Q1 2025
GH Research PLC stock logo
GHRS
GH Research
-$0.61-$0.19+$0.42-$0.19N/AN/A
5/5/2025Q1 2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GH Research PLC stock logo
GHRS
GH Research
N/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/AN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/AN/AN/AN/AN/A
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GH Research PLC stock logo
GHRS
GH Research
N/A
29.71
29.71
Replimune Group, Inc. stock logo
REPL
Replimune Group
0.17
7.95
7.95
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
1.53
5.80
5.75
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/A
32.48
31.73

Institutional Ownership

CompanyInstitutional Ownership
GH Research PLC stock logo
GHRS
GH Research
56.90%
Replimune Group, Inc. stock logo
REPL
Replimune Group
92.53%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/A
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
44.66%

Insider Ownership

CompanyInsider Ownership
GH Research PLC stock logo
GHRS
GH Research
N/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
8.80%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
4.10%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
GH Research PLC stock logo
GHRS
GH Research
1052.03 millionN/AOptionable
Replimune Group, Inc. stock logo
REPL
Replimune Group
21077.09 million70.30 millionOptionable
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
11086.05 million82.52 millionOptionable
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
809.36 million9.07 millionN/A

Recent News About These Companies

Cantor Fitzgerald Predicts TVRD FY2025 Earnings
TVRD Tvardi Therapeutics, Inc.
Tvardi Therapeutics Inc (TVRD)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
GH Research stock logo

GH Research NASDAQ:GHRS

$17.29 +1.30 (+8.13%)
Closing price 04:00 PM Eastern
Extended Trading
$18.35 +1.06 (+6.13%)
As of 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Replimune Group stock logo

Replimune Group NASDAQ:REPL

$12.63 +0.23 (+1.85%)
Closing price 04:00 PM Eastern
Extended Trading
$12.72 +0.08 (+0.67%)
As of 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Syndax Pharmaceuticals stock logo

Syndax Pharmaceuticals NASDAQ:SNDX

$9.25 +0.04 (+0.43%)
Closing price 04:00 PM Eastern
Extended Trading
$9.34 +0.09 (+0.92%)
As of 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Tvardi Therapeutics stock logo

Tvardi Therapeutics NASDAQ:TVRD

$22.74 -3.37 (-12.91%)
As of 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.